LTS and Nualtis Announce Strategic Cooperation to Expand Global Manufacturing Capabilities, Accelerate Market Expansion, and Ensure Customer Success (part 1)

Andernach and Montreal, June 25, 2025 (APA) - LTS LOHMANN Therapie-Systeme AG (LTS), a leading pharmaceutical technology company, and Nualtis (formerly IntelGenx Corp.), an innovator in oral thin film (OTF) drug delivery technology, today announced a strategic collaboration to provide customers with robust, reliable, high-quality and cost-competitive large-scale manufacturing capacities. The collaboration leverages LTS's global expertise in technology transfer, scale-up, and manufacturing, providing Nualtis with resources to scale their innovative OTF products and deliver them to patients worldwide. Through this collaboration, the companies will jointly work towards delivering advanced OTF therapies that improve patient outcomes and address pressing healthcare challenges.

Nualtis has consistently demonstrated success in advancing OTF technologies. As Nualtis expands its pipeline of OTF programs, the collaboration supports scalable growth while offering its partners greater supply chain flexibility and security. The collaboration provides a unique opportunity for Nualtis to strengthen its position as a leader in the OTF market. As global leader in the development and manufacturing of OTF LTS continues to strengthen its position as a platform specialist by leveraging deep expertise to deliver exceptional outcomes for partners and their patients. Committed to innovation and long-term growth, LTS is actively investing in the future through collaboration with other organizations, advanced R&D resources, and expanded manufacturing capacity. These efforts ensure LTS remains at the forefront of oral thin film technology, driving progress across the healthcare landscape. "Teaming up Nualtis’ excellent OTF Formulation platform with LTS’s world-class manufacturing capabilities, allows the two companies to accelerate our shared vision of bringing patient-centric therapeutical solutions to our pharma partners." said Bas van Buijtenen, CEO of LTS. "It provides LTS with an exciting opportunity to extend the reach of our mission of "We CARE, We CREATE, We DELIVER" to a wider range of molecules and therapies." "Nualtis is entering a new phase of growth, and this collaboration ensures we are ready," said Dr. Michael Raven, CEO of Nualtis. "Working with LTS allows us to complement our in-house manufacturing capabilities - giving our partners the confidence that we can support them from early development through to full-scale commercialization." Together, Nualtis and LTS will jointly support customers through every phase of drug development and commercialization by combining innovation with proven execution. The companies remain aligned in their commitment to delivering high-quality, reliable, and scalable OTF solutions that improve treatment outcomes across a broad range of indications. (continues) Kiadó: APA/LTS Lohmann Therapie-Systeme AG ------------------------------------------------------------------- A Nemzeti Közleménytár oldalán található közlemények nem képezik az MTI hírkiadás részét, az MTI által szó szerint továbbított tartalomért minden esetben a közlemény beadója a felelős. A közlemények forrásmegjelöléssel (NKT) szabadon és korlátozás nélkül felhasználhatók. Az NKT szolgáltatással kapcsolatban további információt az nkt@dunamsz.hu elektronikus levelező címen kaphat.